X

Piramal Phytocare Ltd. - (Amalgamated) Stock Analysis

Small Cap
Evaluated by 269 users | BSE: 532979 | NSE: PIRPHYTO |
Pharmaceuticals & Drugs
Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Capital Employed -75.59%-61.62%-6.65%-33.3%-30.38%-34.64%-49.19%3.8%363.04%52.2%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 6.215.82.95.264.56.34.123.825.1
Y-o-Y Gr. Rt.-156.2%-82%83.9%13.7%-23.8%39.2%-34.7%476.5%5.5%
Adjusted EPS (Rs.) -50.9-56.11-2.79-2.48-1.63-1.33-1.260.07-8.65-3.17
Y-o-Y Gr. Rt.-NANANANANANANA-12457.1%NA
Book Value per Share (Rs.) -58.42-114.618.66.154.523.191.921.95-6.71-9.84
Adjusted Net Profit -130-143-7.2-6.4-4.2-3.5-3.30.2-22.5-8.2
Net Op. Cash Flow (Rs. Cr.) -118-99.2-1.7-2.91.10.12.2-0.5-1-13.7
Debt to Cash Flow from Ops -2.77-4.880-0.0900000-0.98
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Piramal Phytocare Ltd. - (Amalgamated) should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 16.9%33.3%58.4%5.5%
Adjusted EPS NANANANA
Book Value per Share 0-216.8-272.40
Share Price -14.5% -17.9% -23.9% 9.7%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Return on Equity (%) 156.2665.495.42-33.67-30.65-34.64-49.223.77363.2238.32
Operating Profit Margin (%) -1631.77-587.35-98.95-45.992.6817.8918.01-1.34-95.02-29.8
Net Profit Margin (%) -2099.82-903.26-253.89-122.98-71.21-76.38-51.634.59-94.34-32.77
Debt to Equity -2.2-1.6600.0200000-0.53
Working Capital Days 7034271,5802051361971572276490
Cash Conversion Cycle 678023710577117991047-123
Entity Percentage Holding
Promoters 56.08%
Institutions 4.01%
Non-Institutions 39.91%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Piramal Phytocare Ltd. - (Amalgamated)'s performance infers:

Piramal Phytocare Ltd. - (Amalgamated) earnings have grown by 0%, whereas share price has depreciated -17.9% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Piramal Phytocare Ltd. - (Amalgamated) share prices over the last 10 years. Here is what we found out:

Piramal Phytocare Ltd. - (Amalgamated) share price has depreciated -17.8% annually over the past ten years.

Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.

PLSL is focused

Piramal Life Sciences Limited (PLSL) is an independent research-driven drug company incorporated in 2001, which was recently demerged from Piramal Healthcare Limited (Formerly known as Nicholas Piramal India Limited). PLSL was formerly the NCE R&D division of NPIL. PLSL has state-of-the-art R&D laboratories built over 200,000 square-feet of space in Mumbai, India and over 300 scientists engaged in drug discovery and development.

PLSL is focused on four therapeutic areas - Cancer, Diabetes, Inflammation and Infectious Diseases. The company has a pipeline of fourteen compounds, including four in clinical trials. PLSL's lead chemical compound, a Cdk-4 inhibitor, has completed two Phase I studies and is being tested in another Phase I/II trial for Multiple Myeloma. PLSL has drug discovery and development agreements with Eli Lilly & Company and Merck & Company, two of the leading pharmaceutical companies in the world.

PLSL has been listed on the National Stock Exchange and the Bombay Stock Exchange since June 2008.

PLSL partners with leading Indian educational institutes to form a research collaborations namely Anna University, Chennai, Indian Institute of Science, Bangalore, Regional Research Laboratory, Jammu, Central Drug Research Institute, Lucknow, National Institute of Immunology, Delhi, National Institute of Oceanography, Goa, and Indian Institute of Chemical Biology, Kolkata.

The company has fourteen compounds in pipeline that includes four in clinical trials. PLSL’s lead chemical compound a Cdk-4 inhibitor has successfully completed two phase studies and will be tested in another Phase I/II trials.

The company has a number of molecules in its research pipeline - in oncology (biological targets: Cyclin Dependent Kinase Cell Cycle inhibitors, Hypoxia Inducible Factor-1a (HIF-1a) Inhibitors, PI3 Kinase Inhibitors), inflammation (TNF - Production / Release Inhibitors, Safer NSAIDs), diabetes (Insulin Sensitizers [non-PPAR], GPR40 Modulators) and infectious disease (Microbial extracts: Antibacterial, Microbial extracts: Antifungal). PLSL also has a comprehensive library of plant extracts and microbial strains.

Research Activities

The company’s research vision and strategy is based on three core principles:Provide scientists state-of-the-art infrastructure to produce world-class science. Leverage India’s bio-diversity and wealth of knowledge on traditional systems of medicines to source drug lead molecules. And collaborate with academic institutions. Following are the research activities:

  • Molecular Biology
  • Biomarker Discovery
  • Medicinal and Synthetic Chemistry
  • Polymer Chemistry
  • Analytical Chemistry
  • Natural Products
  • Herbal Extraction
  • HTS Group
  • Oncology
  • Inflammation
  • Diabetes
  • Vaccine
  • Special Projects
  • Clinical Development
  • Business Development
  • In-vivo Pharmacology
  • Discovery Informatics

Awards & Achievements

  • Dr. Somnath Halder, Group Leader - Medicinal Chemistry, Piramal Life Sciences Limited, wins InnoCentive award for a novel idea to solve a Synthetic Ideation Challenge for an efficient synthesis of vinyl glycine or its hydroxy analogue
  • Dr. Kalpana Joshi, Vice President - Target identification, Piramal Life Sciences Limited, wins the 'Lokmat Maharashtrian of the Year' award for Science and Technology.

Milestones

2008

  • The company gets listed in the NSE and BSE
  • The company entered into a collaboration agreement with Pierre Fabre Laboratories for research in oncology
  • The company made an oral presentation during the 68th Scientific Session of the American Diabetes Association (ADA) being convened at San Francisco, California, USA. The presentation was on preclinical pharmacological data pertaining to a novel, orally active glucose-lowering compound, P1736, discovered and developed at Piramal Life Sciences, Mumbai, using their proprietary insulin resistance cell model.
  • Industry-University/National institutes partnership, were industry and academia will work together to screen such a large number of bacterial isolates. Different academic institutes will isolate organisms’ specific to diverse ecological niches.
  • The company received regulatory approval for the initiation of a Phase I study of a new cancer compound, P-1446A-05, in Canada.
  • The company received regulatory approval for the initiation of a phase-I study in India by Drug Controller General of India (DCGI) of a new cancer compound, P-1446A-05.
  • The company started its Phase II trial of P276 for head and neck cancer

2009

  • The company started phase II trial in USA for its lead cancer compound P 276-00 to treat Mantle cell Lymphoma (MCL) and it is the second IND approved by the US FDA for this compound.
  • The company received regulatory approval by Drug Controller General of India (DCGI) for the initiation of two phase-I/II combination studies of its cancer molecule P276 for pancreatic and head and neck cancer.
  • The company commenced Phase I trial of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada.
  • The company completed Phase I Trials with a New Molecule for Type II Diabetes in Europe
  • The company made a presentation during the 49th Scientific Session of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being convened at San Francisco, California, USA

2010

  • The company introduced Tinefcon, its newly developed natural remedy for Psoriasis at American Academy of Dermatology Convention in Miami, USA

2011

  • The Department of Biotechnology (DBT), Government of India and Piramal Life Sciences Limited (PLSL) have begun Phase II of their Drug Discovery Public Private Partnership to find new drugs from 14000 bioactive cultures discovered in a nationwide search for new drugs from biodiverse habitats across the country in collaboration with 9 national institutes.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback